Annalise Enterprise

Annalise Enterprise is an AI-powered deep-learning software tool designed for the triage and prioritization of chest X-ray studies by identifying critical findings. Its development and FDA clearance are supported by comprehensive performance evaluations demonstrating high sensitivity and specificity for conditions like pneumothorax, aiming to improve worklist turn-around times and support clinician review.

The U.S. Food & Drug Administration has completed its evaluation of Annalise Enterprise, determining that the system is substantially equivalent to legally marketed devices for its stated indications for use. This conclusion permits Annalise -AI to market the device. Its use is subject to ongoing compliance with federal regulations, including requirements for annual registration, device listing, good manufacturing practices, proper labeling, and prohibitions against misbranding or adulteration. Annalise Enterprise is an artificial intelligence (AI) software tool designed to aid in the triage and prioritization of chest X-ray studies. It uses a deep-learning algorithm to identify suspected findings such as pneumothorax, tension pneumothorax, pleural effusion, pneumoperitoneum, and vertebral compression fractures. The software integrates with image management systems to provide notifications, which helps prioritize studies for clinician review without decreasing existing worklist priorities or being used for standalone clinical decision-making. Comprehensive performance evaluations confirmed the device's high sensitivity and specificity for the identified conditions, demonstrating its effectiveness in improving worklist turn-around times and supporting its safety and efficacy.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. What specific data sets and patient demographics were used to train and validate the deep-learning algorithm, and how might performance vary across diverse populations?; How does Annalise Enterprise's performance for less common or subtle findings compare to its reported high sensitivity and specificity for the explicitly mentioned conditions?; What are the false positive and false negative rates for each identified condition, and what is the clinical impact of these errors on patient management and clinician workload?; What are the long-term impacts of integrating Annalise Enterprise on radiologist burnout, diagnostic accuracy improvements, and overall healthcare costs in a real-world clinical setting?; Are there any specific imaging modalities or acquisition protocols that might affect the accuracy or reliability of Annalise Enterprise's findings?